跳到正文
原文
NEJM 新英格兰医学杂志· Thomas D. NortonRegeneron Pharmaceuticals, Tarrytown, NYJorg TaubelRichmond Pharmacology, LondonGavin H. ImperatoSonya Aziz-ZamanJane WitkinJutta MillerKusha A. MohammadiShunguang WangTerri SwansonMadison StomsXiping ChengJessica D’AntonioShehla HabibDavid WorkmanJustin ChoYogesh PatelVidya XavierChao ChenDavid J. SmithSean SmithSusana PereiraDonato ForlenzaJoette PindarMeredith CrosbyShawn FidottaMauricio LealFady TaniosViktoria GusarovaMark SleemanJennifer HamiltonJohn DavisDinko Gonzalez TrotterRong LiuBret MusserEd CoxNed BraunsteinNiek VerweijLuca A. LottaGeorge D. YancopoulosAris BarasGary A. HermanDavid J. Ledererfor the ALN-CIDEB-NASH-2486 Study Investigators, Regeneron Genetics Center (RGC), Geisinger Health System–RGC DiscovEHR Collaboration, Penn Medicine Biobank, Colorado Center for Personalized Medicine, Mayo Clinic–RGC Project Generation, Malmö Diet and Cancer Study, Indiana University School of Medicine (Indiana-CLDB), UCLA Health–RGC ATLAS Collaboration, Mount Sinai Million Health Discoveries Program, and the University of Texas Southwestern, Dallas Biobank*Regeneron Pharmaceuticals, Tarrytown, NY·· 13 天前AI 评分32

A Liver-Targeted CIDEB siRNA 在成人MASLD中的研究

A Liver-Targeted CIDEB siRNA in Adults with MASLD

AI 导读

一项针对成人代谢相关脂肪性肝病(MASLD)的临床前研究表明,靶向肝脏的CIDEB siRNA具有潜在治疗效果。该研究结果有待进一步临床验证。

来源:NEJM 新英格兰医学杂志 · nejm.org